District/county level | Healthcare facility level | |||
Limitation underlying absence of the diagnostic test | Xpert MTB/RIF (N=76) | LPA (N=201) | Xpert MTB/RIF (N=34) | LPA (N=138) |
Under financing | 91% | 55% | 56% | 21% |
Procurement difficulties | 9% | 7% | 6% | 8% |
Inadequate human resource | 1% | 3% | 24% | 0% |
No water | 1% | 0% | 26% | 0% |
No electricity | 0% | 1% | 26% | 0% |
Biosafety issues | 3% | 1% | 0% | 0% |
Only available at regional hospital | 0% | 3% | 0% | 3% |
Not aware of the test | 0% | 33% | 0% | 49% |
The respondents were district (Uganda and Tanzania) and/or county (Kenya) health officers and healthcare practitioners.
LPA, line probe assay.